Acacia Pharma Group plc

2021 Mid-Year Results Presentation September 30, 2021

Transforming Medicine Advancing Care

Important Notice

The information contained in this presentation (this "presentation") has been prepared by Acacia Pharma Group plc ("the Company") as at the date of this presentation and is subject to updating, completion, revision, further verification and amendment without notice. This presentation is for general information only and is the property of the Company. Making this presentation available in no circumstances whatsoever implies the existence of a commitment or contract by or with the Company, or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents for any purpose.

This presentation has not been approved by the United Kingdom Listing Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000 ("FSMA")), by the Belgian Financial Services and Markets Authority or otherwise, by the regulated market of Euronext Brussels. This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or on the completeness, accuracy or fairness thereof.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or its directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise. In addition, in issuing this presentation, the Company undertakes no obligation to update or to correct any inaccuracies which may become apparent in this presentation. Notwithstanding the aforesaid, nothing in this paragraph shall exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

The statements contained in this presentation may include "forward looking statements" that express expectations of future events or results. All statements based on future expectations rather than on historical facts are forward looking statements that involve a number of risks and uncertainties and the Company cannot give assurance that such statements will prove to be correct. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. The Company gives no undertaking to update forward looking statements to reflect any changes in expectations, events, conditions or circumstances upon which such statements are made.

The presentation should not be considered a recommendation by the Company or any of its affiliated entities, or any of its or their respective subsidiaries, directors, officers, representatives, employees, advisers or agents in connection with any purchase of or subscription for securities of the Company.

This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, this presentation should not be copied or distributed by recipients and should not be distributed by any means including electronic transmission, to persons with addresses in the United States of America, Canada, Australia, South Africa or Japan their possessions or territories or to any citizens thereof, or to any corporation, partnership or such entity created or organised under the laws thereof. Any such distribution contrary to the above could result in a violation of the laws of such countries.

2

Acacia Pharma Group - Executing well despite a challenging environment

Commercial launches of Barhemsys® and Byfavo® both showing good progress

  • Formulary access is the most important indicator of success for our launches this year
  • Strong, experienced team has effectively engaged with customers both virtually and live when possible
  • Currently on track to meet our annual formulary goals for both products
  • Customers have provided very positive feedback on their initial experiences with the products

Engagement with KOLS and key institutions remains high with P4 studies to support expanded usage

  • Have begun the Byfavo pediatric study
  • There has been significant KOL interest in further studying Byfavo
  • Partnering with key institutions to begin the Barhemsys PROMPT study to gather real-world evidence

Continued strong corporate progress

  • MAA for Barhemsys under review in major EU markets - progressing international licensing agreements
  • Raised €27m in February equity offering
  • Made early repayment of Hercules loan facility
  • Deb Hussain appointed Chief Commercial Officer

3

Barhemsys® and the PONV Opportunity

Barhemsys

Barhemsys is the only FDA-approveddrug for PONV rescue after failed prophylaxis1

Addresses the major

Dopamine D2/D3 antagonist with broad, differentiated label

unmet need in PONV

Offers significant economic savings to hospital vs current standard of care

Estimated ~65m eligible surgeries annually, ~49m patients receive preventative antiemetics3

Large US market

Estimated ~16m patients still develop PONV and need rescue treatment3

opportunity in PONV2

Total addressable PONV rescue market estimated at ~$2.7 billion/year4

Convenient, easy to use, & secure supply chain

  • 5-yearroom temperature shelf-life
  • Fits in auto-dispensing (Pyxis™) machines
  • Substantial product inventory to mitigate potential supply chain disruption

Can help with COVID surgical backlogs

  • "The OR accounts for up to 65% of hospital profit margin" - Becker's Hospital Review5
  • Non-essentialsurgery cancellations create significant backlogs
  • Shorter time in PACU (recovery room) can help increase surgical throughput

1 FDA labels for other recommended treatments do not include treatment after failed prophylaxis, 2 This is the belief of the Company. 3 Company market size estimates based upon: 2006 National Hospital Discharge Survey; National

Survey of Ambulatory Surgery, 2006 (as revised in 2009); LSSG Quantitative Research November 2014; Apfel, NEJM 2004. Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative

4

market research responses. 4 Based upon WAC price of $85 per 10mg rescue dose with, on average, 2 rescue doses per patient, and the above estimates 5 How to rebuild surgical revenue after COVID-19, Becker's Hospital

Review, accessed viahttps://www.beckershospitalreview.com/strategy/how-to-rebuild-surgical-revenue-after-covid-19-even-if-you-just-lost-60-of-your-or-volume.html

Targeting PONV Rescue Market

~65m invasive

~49m receive

~32% fail

~16m patients

surgical

per year require

antiemetic

prophylaxis and

procedures per

PONV rescue

prophylaxis1

get PONV1

year (US)1

treatment

~18m high-risk patients per year eligible for combination prophylaxis1

Total estimated addressable market in PONV rescue $2.7B per year

Secondary market in combination prophylaxis in highest-risk patients, estimated to be worth $765M per year2

1 Company market size estimates based upon: 2006 National Hospital Discharge Survey; National Survey of Ambulatory Surgery, 2006 (as revised in 2009); LSSG Quantitative Research November 2014; Apfel et al, 2004.

5

Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses. 2 Based on WAC price of $85 per 10 mg rescue dose and average 2 rescue doses per

patient; $42.50 per 5 mg prophylaxis dose.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Acacia Pharma Group plc published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 05:11:09 UTC.